Literature DB >> 33257802

Risk factors for myopia at 1-year corrected age following laser photocoagulation for retinopathy of prematurity.

Yujiro Mori1, Mitsuru Arima2, Emi Ueda1, Kohta Fujiwara1, Eiko Seki1, Takahito Nakama1, Shoko Tsukamoto1, Masato Akiyama1, Koh-Hei Sonoda1.   

Abstract

BACKGROUND/
OBJECTIVES: The prevalence of myopia is higher in preterm infants who underwent laser photocoagulation (LPC) for retinopathy of prematurity (ROP). The aim of this study was to investigate factors associated with myopia in preterm infants who undergo LPC for ROP. SUBJECTS/
METHODS: We retrospectively analysed the medical records of preterm infants born at Kyushu University Hospital (October 2008-March 2018) at ≤32 weeks of gestational age or with birth weight ≤1500 g. We evaluated the associations between nine clinical factors and the spherical equivalent at 1-year corrected age by performing multivariable linear regression in LPC-treated ROP patients.
RESULTS: Among the 485 infants enroled, 76 developed ROP requiring treatment. Of these, 71 underwent LPC, which was provided to 63 infants as the primary treatment (LPC alone or the combination therapy of LPC and intravitreal injection of bevacizumab [IVB]) and to eight infants as additional LPC after IVB monotherapy. The results of a refractive examination at 1-year corrected age were available for 110 eyes of 56 infants (78.9%). The mean ± standard deviation of the SE value was -0.5 ± 3.0 dioptres (D). Multivariable linear regression analysis revealed a significant association between laser spot count and SE value (ß = -0.081 ± 0.040 D per 100 spots [mean ± standard error], p = 0.045).
CONCLUSIONS: Our results suggest that an increased laser spot count observed during ROP treatment associates with myopia.
© 2020. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33257802      PMCID: PMC8452716          DOI: 10.1038/s41433-020-01321-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   4.456


  2 in total

1.  Outcome of solid-state 532 nm green laser in high-risk retinopathy of prematurity at a tertiary care centre in India.

Authors:  Kanika Chhabra; Prempal Kaur; Karamjit Singh; Anand Aggarwal; Dharamvir Chalia
Journal:  Int Ophthalmol       Date:  2017-02-15       Impact factor: 2.031

2.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004
  2 in total
  2 in total

1.  Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity.

Authors:  Qiong Zou; Yan-Qiong Zhu; Feng-Jun Zhang; Qiu-Ping Liu
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.779

2.  Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.

Authors:  Emily Wiecek; James D Akula; Deborah K Vanderveen; Iason S Mantagos; Carolyn Wu; Amber-Lee Curran; Hanna De Bruyn; Bridget Peterson; Anne B Fulton
Journal:  Am J Ophthalmol       Date:  2022-03-31       Impact factor: 5.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.